- Home
- DVAX vs NCMI Comparison
DVAX vs NCMI Comparison
Compare DVAX & NCMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- NCMI
- Stock Information
- Founded
- DVAX 1996
- NCMI 2005
- Country
- DVAX United States
- NCMI United States
- Employees
- DVAX N/A
- NCMI N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- NCMI Advertising
- Sector
- DVAX Health Care
- NCMI Consumer Discretionary
- Exchange
- DVAX Nasdaq
- NCMI Nasdaq
- Market Cap
- DVAX 1.3B
- NCMI 434.8M
- IPO Year
- DVAX 2004
- NCMI 2007
- Fundamental
- Price
- DVAX $9.75
- NCMI $4.85
- Analyst Decision
- DVAX Buy
- NCMI Strong Buy
- Analyst Count
- DVAX 4
- NCMI 4
- Target Price
- DVAX $26.50
- NCMI $7.00
- AVG Volume (30 Days)
- DVAX 2.0M
- NCMI 429.6K
- Earning Date
- DVAX 11-06-2025
- NCMI 11-04-2025
- Dividend Yield
- DVAX N/A
- NCMI 2.48%
- EPS Growth
- DVAX N/A
- NCMI N/A
- EPS
- DVAX N/A
- NCMI N/A
- Revenue
- DVAX $316,268,000.00
- NCMI $235,300,000.00
- Revenue This Year
- DVAX $23.23
- NCMI $5.40
- Revenue Next Year
- DVAX $16.57
- NCMI $14.48
- P/E Ratio
- DVAX N/A
- NCMI N/A
- Revenue Growth
- DVAX 26.66
- NCMI 13.34
- 52 Week Low
- DVAX $9.20
- NCMI $4.12
- 52 Week High
- DVAX $14.63
- NCMI $7.60
- Technical
- Relative Strength Index (RSI)
- DVAX 43.66
- NCMI 58.16
- Support Level
- DVAX $9.20
- NCMI $4.72
- Resistance Level
- DVAX $9.94
- NCMI $5.03
- Average True Range (ATR)
- DVAX 0.31
- NCMI 0.19
- MACD
- DVAX -0.01
- NCMI 0.06
- Stochastic Oscillator
- DVAX 50.00
- NCMI 78.05
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.